Walleye Capital
ARQT icon

Walleye Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Walleye Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Sell
50,460
-118,144
-70% -$3.02M 0.01% 1919
2025
Q4 		$4.9M Buy
168,604
+147,902
+714% +$3.79M 0.03% 1165
2025
Q3 		$390K Sell
20,702
-4,227
-17% -$66.7K ﹤0.01% 2806
2025
Q2 		$350K Buy
24,929
+24,210
+3,367% +$339K ﹤0.01% 2935
2025
Q1 		$11.2K Buy
+719
New +$10.1K ﹤0.01% 4058
2024
Q1 		– Sell
-323,600
Closed -$1.05M – 5405
2023
Q4 		$1.05M Buy
+323,600
New +$880K 0.01% 2303
2022
Q2 		– Sell
-75,553
Closed -$1.46M – 2342
2022
Q1 		$1.46M Sell
75,553
-7,867
-9% -$133K 0.04% 468
2021
Q4 		$1.73M Buy
+83,420
New +$1.66M 0.06% 365

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return